Open Nav

Ativo TX (dba IL-2Rx Inc.)

  • Sally Ann Reiss, Ativo TX, dba Il-2rx Inc

Strategic partnerships and investor financing

  • Date:Wednesday, October 17
  • Time:10:00 AM - 10:15 AM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Ativo TX was founded by an experienced immunology clinician, a molecular biologist, and a chemist (as a spinout from Stanford Medical School). Ativo TX is creating new drug therapies that target a cell-mediated immune response pathway prevalent in major Autoimmune Disorders (Multiple Sclerosis, Lupus, Rheumatoid Arthritis, Type 1 Diabetes). Ativo TX has a patent-protected, novel platform technology that utilizes existing FDA approved drugs in a protein-drug conjugate model. Ativo TX’s has established strategic partnerships to bring Ativo’s lead candidate drugs to market (SAB, Stanford & IBMP/Fiocruz)
  • Company Website:www.il2rx.com
  • Company HQ City:San Jose, California
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Chariman of the Board, Dr. C.G. Fathman
  • Year Founded:2017
  • Main Therapeutic Focus:Immunology
  • Lead Product in Development :Autoimmune Disease Protein Drug Conjugate
  • Development Phase of Primary Product:Discovery
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :4
  • Previous and Current Investors:Friends and family
  • Size of Last Investment Round:680,000
  • Total Amount Raised to Date, In All Rounds:680,000
Speakers
Sally Ann Reiss
Ativo TX, dba Il-2rx Inc
Back